JP2023509698A5 - - Google Patents
Info
- Publication number
- JP2023509698A5 JP2023509698A5 JP2022541198A JP2022541198A JP2023509698A5 JP 2023509698 A5 JP2023509698 A5 JP 2023509698A5 JP 2022541198 A JP2022541198 A JP 2022541198A JP 2022541198 A JP2022541198 A JP 2022541198A JP 2023509698 A5 JP2023509698 A5 JP 2023509698A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- individual
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957535P | 2020-01-06 | 2020-01-06 | |
| US62/957,535 | 2020-01-06 | ||
| PCT/US2021/012367 WO2021142030A1 (en) | 2020-01-06 | 2021-01-06 | Methods of treating conditions related to the s1p1 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509698A JP2023509698A (ja) | 2023-03-09 |
| JP2023509698A5 true JP2023509698A5 (enExample) | 2023-12-26 |
Family
ID=76788331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541198A Pending JP2023509698A (ja) | 2020-01-06 | 2021-01-06 | Ｓ１ｐ１受容体に関連した状態の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230338336A1 (enExample) |
| EP (1) | EP4087562A4 (enExample) |
| JP (1) | JP2023509698A (enExample) |
| KR (1) | KR20220124209A (enExample) |
| CN (1) | CN115066242A (enExample) |
| AU (1) | AU2021205465A1 (enExample) |
| BR (1) | BR112022012846A2 (enExample) |
| CA (1) | CA3166828A1 (enExample) |
| IL (1) | IL294071A (enExample) |
| MX (1) | MX2022008342A (enExample) |
| TW (1) | TW202135804A (enExample) |
| WO (1) | WO2021142030A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240065283A (ko) * | 2021-09-23 | 2024-05-14 | 브리스톨-마이어스 스큅 컴퍼니 | Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법 |
| WO2023135506A1 (en) * | 2022-01-13 | 2023-07-20 | Arena Pharmaceuticals, Inc. | Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment |
| KR102541577B1 (ko) | 2022-10-21 | 2023-06-13 | 주식회사 넥스트젠바이오사이언스 | S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1469863A2 (en) * | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| CN104311472B9 (zh) * | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| PL2498610T5 (pl) * | 2009-11-13 | 2024-11-04 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
| HUE036391T2 (hu) * | 2009-11-13 | 2018-07-30 | Celgene Int Ii Sarl | Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások |
| CN105130922A (zh) * | 2009-11-13 | 2015-12-09 | 瑞塞普托斯公司 | 选择性的杂环1-磷酸鞘氨醇受体调节剂 |
| US9198911B2 (en) * | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| CN110520124A (zh) * | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
-
2021
- 2021-01-06 WO PCT/US2021/012367 patent/WO2021142030A1/en not_active Ceased
- 2021-01-06 IL IL294071A patent/IL294071A/en unknown
- 2021-01-06 JP JP2022541198A patent/JP2023509698A/ja active Pending
- 2021-01-06 US US17/790,632 patent/US20230338336A1/en not_active Abandoned
- 2021-01-06 BR BR112022012846A patent/BR112022012846A2/pt not_active IP Right Cessation
- 2021-01-06 TW TW110100496A patent/TW202135804A/zh unknown
- 2021-01-06 KR KR1020227026729A patent/KR20220124209A/ko not_active Withdrawn
- 2021-01-06 AU AU2021205465A patent/AU2021205465A1/en not_active Abandoned
- 2021-01-06 CA CA3166828A patent/CA3166828A1/en active Pending
- 2021-01-06 CN CN202180013704.0A patent/CN115066242A/zh not_active Withdrawn
- 2021-01-06 EP EP21738729.9A patent/EP4087562A4/en not_active Withdrawn
- 2021-01-06 MX MX2022008342A patent/MX2022008342A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7128536B2 (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| JP2022516662A5 (enExample) | ||
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| US5661171A (en) | Controlled release pilocarpine delivery system | |
| JP3929618B2 (ja) | 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物 | |
| EP4289478A2 (en) | Edaravone pharmaceutical composition | |
| JP2013121976A (ja) | 難溶性薬剤の改善された溶解プロファイルを有する医薬組成物 | |
| JP2022533968A5 (enExample) | ||
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| JP2024531188A5 (enExample) | ||
| EP3600276B1 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| WO2005094832A1 (en) | Compositions comprising meloxicam | |
| AU2003287488B2 (en) | Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally | |
| JPH05148139A (ja) | イブプロフエン含有解熱鎮痛剤 | |
| JP3170855B2 (ja) | イブプロフェン含有解熱鎮痛剤 | |
| WO2025133628A1 (en) | Use of alvelestat in specific patients | |
| JP4113257B2 (ja) | 口腔乾燥症の処理におけるコリンエステラーゼ阻害剤の使用 | |
| JPH07126163A (ja) | 制御放出性ピロカルピン送達システム | |
| MX2013005716A (es) | Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma. | |
| JP2022550458A5 (enExample) | ||
| JP2002523363A (ja) | 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用 | |
| HUP0100365A2 (hu) | Kombinációs terápia AIDS kezelésére | |
| EP2146713B1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| JP7067031B2 (ja) | 固形製剤 |